Skip to content

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL
Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification
Don’t miss SOHO 2026 poster walks
Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM
CAR-T improves survival, reduces hospital use in R/R LBCL

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Jerald Radich, MD

Cellular Therapy

Jerald Radich, MD

Leukemia

Jerald Radich, MD

Lymphoma

Jerald Radich, MD

Multiple Myeloma

Jerald Radich, MD

Myelodysplastic Syndromes

Jerald Radich, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

April 9, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Jerald Radich, MD

Jerry Radich of fred hutch

Jerald Radich, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
573 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Lymphoma, Indolent B-Cell Lymphomas

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

April 8, 2026

SOHO Asia 2026, Leukemia, Acute Myeloid Leukemia, News, Video Interviews

Dr. Feng-Ming Tien on immune landscapes and the future

April 8, 2026

poster_walks_960x520

SOHO 2026, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, News, Society Updates

Don’t miss SOHO 2026 poster walks

April 7, 2026

Japanese flag

Cellular Therapy, Multiple Myeloma, News

Japan’s PMDA clears phase 3 trial of eque-cel in

April 6, 2026

hospital bed

Cellular Therapy, Lymphoma, Aggressive B-Cell Lymphomas

CAR-T improves survival, reduces hospital use in R/R LBCL

April 3, 2026

SOHO Turkey

Ambassador Program, News, Society Updates

13th annual SOHO Türkiye meeting to be held April

April 2, 2026

Top Categories

Cellular Therapy

65

Leukemia

101

Lymphoma

110

Multiple Myeloma

86

Myelodysplastic Syndromes

33

Myeloproliferative Neoplasms

21

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Jerald Radich, MD

Cellular Therapy

Jerald Radich, MD

Leukemia

Jerald Radich, MD

Lymphoma

Jerald Radich, MD

Multiple Myeloma

Jerald Radich, MD

Myelodysplastic Syndromes

Jerald Radich, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification

poster_walks_960x520

Don’t miss SOHO 2026 poster walks

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.